{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:37:13Z","timestamp":1784309833398,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jad.2024.07.128","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T21:37:46Z","timestamp":1721252266000},"page":"589-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A replication study using the World Health Organization pharmacovigilance database (VigiBase\u00ae) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists"],"prefix":"10.1016","volume":"363","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-1112","authenticated-orcid":false,"given":"Angela T.H.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-2191","authenticated-orcid":false,"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jad.2024.07.128_bb0005","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/add.15820","article-title":"Risk of self-harm or suicide associated with specific drug use disorders, 2004-2016: a population-based cohort study","volume":"117","author":"Chai","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jad.2024.07.128_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.jad.2024.07.128_bb0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.07.128_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.07.128_bb0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2024.07.128_bb0030","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1038\/s41380-021-01167-1","article-title":"Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al [review of unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al]","volume":"26","author":"Heifets","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"49","key":"10.1016\/j.jad.2024.07.128_bb0035","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305772120","article-title":"Ketamine and the neurobiology of depression: toward next-generation rapid-acting antidepressant treatments","volume":"120","author":"Krystal","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jad.2024.07.128_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/JCP.0000000000000441","article-title":"A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect","volume":"36","author":"Lee","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2024.07.128_bb0045","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/brainsci11070856","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive\u2013compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature","volume":"11","author":"Martinotti","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.jad.2024.07.128_bb0050","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2024.07.128_bb0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2024.07.128_bb0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry: Official Journal of the World Psychiatric Association"},{"key":"10.1016\/j.jad.2024.07.128_bb0065","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration adverse event reporting system (FAERS)","author":"McIntyre","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.jad.2024.07.128_bb0070","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ejp.1317","article-title":"Intraoperative S-ketamine for the reduction of opioid consumption and pain one year after spine surgery: a randomized clinical trial of opioid-dependent patients","volume":"23","author":"Nielsen","year":"2019","journal-title":"Eur. J. Pain"},{"issue":"12","key":"10.1016\/j.jad.2024.07.128_bb0075","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1176\/appi.ajp.2021.21060653","article-title":"Mechanisms of action of ketamine and esketamine [review of mechanisms of action of ketamine and esketamine]","volume":"178","author":"Schatzberg","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.128_bb0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2024.01.262","article-title":"Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine\/esketamine","volume":"351","author":"Singh","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.07.128_bb0085","unstructured":"VigiAccess. (n.d.-a). Retrieved May 18, 2024, from https:\/\/www.vigiaccess.org\/."},{"key":"10.1016\/j.jad.2024.07.128_bb0090","unstructured":"VigiAccess. (n.d.-b). Retrieved July 1, 2024, from https:\/\/www.vigiaccess.org\/."},{"key":"10.1016\/j.jad.2024.07.128_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2023.4945","article-title":"The rapidly shifting ketamine landscape in the US","author":"Wilkinson","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2024.07.128_bb0100","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.128_bb0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","article-title":"The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis","volume":"134","author":"Xiong","year":"2021","journal-title":"J. Psychiatr. Res."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724011868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724011868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T23:06:57Z","timestamp":1725145617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724011868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":21,"alternative-id":["S0165032724011868"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.128","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A replication study using the World Health Organization pharmacovigilance database (VigiBase\u00ae) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}